Parkinson's breakthrough? stem cells show promise in early trial
NCT ID NCT05887466
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new stem cell treatment for Parkinson's disease in 12 people who had been diagnosed at least 5 years earlier. The treatment uses dopamine-producing cells made from embryonic stem cells, injected into the brain. The main goal was to check safety, but researchers also looked for signs that it might slow or reverse the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
embryonic stem cell-derived dopamine progenitor cells
What this could lead to
If this works, it could point toward a treatment that slows or stops Parkinson's progression, or even helps repair damaged brain areas.
What could go wrong
This is a very early, small trial (12 people) focused mainly on safety. The treatment may not work, and there are risks like tumors or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, 03722, South Korea